Ill-conceived regulations and bureaucratic red tape emanating from the U.S. Food and Drug Administration (FDA) have inhibited competition and hiked EpiPen prices, according to a new report by National Center for Policy Analysis Senior Fellow Devon Herrick. “Epinephrine has long since lost patent protection. The epinephrine injected by the EpiPen is available in ampules costing…